L
Linda Ozoemena
Researcher at St Thomas' Hospital
Publications - 29
Citations - 636
Linda Ozoemena is an academic researcher from St Thomas' Hospital. The author has contributed to research in topics: Epidermolysis bullosa & Epidermolysis bullosa simplex. The author has an hindex of 13, co-authored 27 publications receiving 530 citations. Previous affiliations of Linda Ozoemena include Guy's and St Thomas' NHS Foundation Trust & St. John's University.
Papers
More filters
Journal ArticleDOI
A Homozygous Nonsense Mutation within the Dystonin Gene Coding for the Coiled-Coil Domain of the Epithelial Isoform of BPAG1 Underlies a New Subtype of Autosomal Recessive Epidermolysis Bullosa Simplex
Richard Groves,Lu Liu,Patricia J.C. Dopping-Hepenstal,Hugh S. Markus,Patricia A. Lovell,Linda Ozoemena,Joey Lai-Cheong,Joey Lai-Cheong,Jeffrey Gawler,Katsushi Owaribe,Takashi Hashimoto,Jemima E. Mellerio,Jemima E. Mellerio,John B. Mee,John A. McGrath +14 more
TL;DR: The clinicopathological findings expand the molecular basis of EB by identifying BPAG1-e pathology in a new form of autosomal recessive EB simplex, which has lifelong generalized trauma-induced spontaneous blisters and erosions, particularly around the ankles.
Journal ArticleDOI
Whole-exome sequencing improves mutation detection in a diagnostic epidermolysis bullosa laboratory
Takuya Takeichi,Takuya Takeichi,Lin Liu,Kenneth Fong,Linda Ozoemena,James R. McMillan,Amr Salam,Peter Campbell,Peter Campbell,Masashi Akiyama,Jemima E. Mellerio,Jemima E. Mellerio,Whi McLean,Michael A. Simpson,John A. McGrath,John A. McGrath +15 more
TL;DR: Current approaches in EB diagnostics involve skin biopsy for immunohistochemistry and transmission electron microscopy, and Sanger sequencing of candidate genes, and may fail to identify pathogenic mutations in ~15% of cases.
Journal ArticleDOI
Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.
Su M. Lwin,Farhatullah Syed,Wei Li Di,Tendai Kadiyirire,Lu Liu,Alyson Guy,Anastasia Petrova,Alya Abdul-Wahab,Fiona Reid,Rachel Phillips,Maria Elstad,Christos Georgiadis,Sophia Aristodemou,Patricia A. Lovell,James R. McMillan,John B. Mee,S. Miskinyte,M. Titeux,Linda Ozoemena,Rashida Pramanik,Sonia Serrano,Racheal Rowles,Clarisse Maurin,Elizabeth Orrin,Magdalena Martinez-Queipo,Magdalena Martinez-Queipo,Ellie Rashidghamat,Christos Tziotzios,Alexandros Onoufriadis,Mei Chen,Lucas Chan,Farzin Farzaneh,Marcela Del Rio,Jakub Tolar,Johann W. Bauer,Fernando Larcher,Michael Antoniou,Alain Hovnanian,Adrian J. Thrasher,Jemima E. Mellerio,Waseem Qasim,John A. McGrath +41 more
TL;DR: In this article, the authors developed a self-inactivating lentiviral platform encoding a codon-optimized COL7A1 cDNA under the control of a human phosphoglycerate kinase promoter for phase I evaluation.
Journal ArticleDOI
Impact of next generation sequencing on diagnostics in a genetic skin disease clinic
Takuya Takeichi,Arti Nanda,Lu Liu,Amr Salam,Patrick Campbell,Kenneth Fong,Masashi Akiyama,Linda Ozoemena,Kristina L. Stone,Hejab Al-Ajmi,Michael A. Simpson,John A. McGrath +11 more
TL;DR: The observations highlight the value of whole‐exome sequencing, in combination with robust bioinformatics analysis, in determining the precise molecular pathology and clinical diagnosis in patients with genetic skin disorders, notably at an early stage in the clinical evaluation of these often complex disorders.
Journal ArticleDOI
Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa
Ellie Rashidghamat,Tendai Kadiyirire,Salma Ayis,Gabriela Petrof,Lu Liu,Venu Pullabhatla,Chrysanthi Ainali,Alyson Guy,Sophia Aristodemou,James R. McMillan,Linda Ozoemena,John B. Mee,Rashida Pramanik,Alka Saxena,Rosamund Nuamah,Emanuele de Rinaldis,Sonia Serrano,Clarisse Maurin,Magdalena Martinez-Queipo,Su M. Lwin,Dusko Ilic,Anna E. Martinez,Francesco Dazzi,Ineke Slaper-Cortenbach,Kasper Westinga,Sabrina Zeddies,Marcel P. H. van den Broek,Alexandros Onoufriadis,Jemima E. Mellerio,John A. McGrath +29 more
TL;DR: MSC infusion is safe in RDEB adults and can have clinical benefits for at least 2 months, and if the cells improve wound healing and quality of life.